50 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does not constitute an offer … . Accordingly, there can be no assurance that we will not be a PFIC in 2024 or any future taxable year.
If we are a PFIC for any taxable year during which
6-K
EX-99.1
IFRX
InflaRx N.V.
28 Jun 24
Leerink Partners LLC
4:55pm
agreement setting forth the terms of such sale. The Company acknowledges and agrees that (i) there can be no assurance that the Agent will be successful … , to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
424B5
wjkpt7s1mde1z
12 Jul 23
Prospectus supplement for primary offering
12:00am
F-3
mvccc
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
EX-1.1
cwuqd6opdowe530e
13 Apr 23
Current report (foreign)
4:01pm
424B5
ckqme7h9vqe0
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
ly5ba6z2ui48tac
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.2
h1skn ot2tp5
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.1
wgqzc
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.2
0ct51wg2gh0
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
7eoa thaoj90ew7
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.2
w54wzil3tl8otzi
10 Jan 22
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
7:30am
6-K
EX-99.2
l8g pg8mbqb199
15 Nov 21
Current report (foreign)
7:36am
6-K
EX-99.2
2zu0m454 qftuaq
27 Oct 21
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
7:31am